6938 — Suzhou Ribo Life Science Co Cashflow Statement
0.000.00%
- HK$9.64bn
- HK$9.94bn
- CNY148.51m
Annual cashflow statement for Suzhou Ribo Life Science Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -437 | -257 | -285 |
| Depreciation | |||
| Amortisation | |||
| Non-Cash Items | 90.3 | 41.8 | 50.5 |
| Unusual Items | |||
| Equity in Net Earnings/Losses | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 8.11 | 106 | -94.7 |
| Change in Accounts Receivable | |||
| Change in Inventories | |||
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Payable / Accrued Expenses | |||
| Change in Other Liabilities | |||
| Other Operating Cash Flow | |||
| Cash from Operating Activities | -288 | -60.7 | -281 |
| Capital Expenditures | -40.6 | -23.4 | -9.89 |
| Purchase of Fixed Assets | |||
| Purchase / Acquisition of Intangibles | |||
| Other Investing Cash Flow Items | 16.2 | 2.71 | 10.2 |
| Sale of Business | |||
| Sale of Fixed Assets | |||
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Other Investing Cash Flow | |||
| Cash from Investing Activities | -24.5 | -20.7 | 0.287 |
| Financing Cash Flow Items | -14.5 | -15.1 | 249 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | -4.77 | 39.5 | 522 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -314 | -42.4 | 239 |